We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Comen Medical

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Jan 2022 - 27 Jan 2022

Guided Coagulation System Treats Persistent AF

By HospiMedica International staff writers
Posted on 02 Nov 2021
Print article
Image: The ablation tip of the EPi-Sense Guided Coagulation System (Photo courtesy of AtriCure)
Image: The ablation tip of the EPi-Sense Guided Coagulation System (Photo courtesy of AtriCure)
A new epicardial ablation device helps treat long-standing persistent atrial fibrillation (Afib) in patients who do not respond endocardial catheter ablation alone.

The AtriCure (Mason, OH, USA) EPi-Sense Guided Coagulation System is intended for use in combination with an ablation catheter to treat persistent Afib when anti-arrhythmic drugs (AADs) are not working, or cannot be tolerated by the patient. The minimally invasive surgical device is video-guided to the epicardial surface of the posterior left atrium via a cannula inserted below the sternum. The device is then used to send intense pulses of radiofrequency (RF) energy to destroy the tissue.

At the same time, an ablation catheter inserted percutaneously through the femoral vein is guided towards the interior wall of the left atrium. The tip of the ablation catheter delivers concomitant RF energy to address lesion gaps to tissues inside the heart that are causing the abnormal heart rhythm. A recent study showed that when the two devices are used in unison, the hybrid procedure is 35% more efficient at 18 months than cardiac ablation alone, with a 37% reduction in Afib burden also evident.

“The long-standing persistent Afib population represents over three million patients in the United States alone, or nearly half of all diagnosed Afib patients. These patients are very difficult to treat with catheter ablation alone,” said Michael Carrel, President and CEO of AtriCure. “In addition to superior clinical results, the [EPi-Sense] procedure significantly improves electrophysiology lab efficiency by reducing endocardial ablation times by over 40 minutes, improving throughput, and enabling more patients to be treated.”

AF occurs when the heart's two upper chambers beat erratically, which can lead to serious adverse events such as thrombi travelling from the heart to obstruct arteries supplying the brain, causing stroke, or other parts of the body causing tissue damage. In one form, paroxysmal AF, patients have bouts of erratic beats that begin spontaneously and usually last less than a week. AADs can often control the heart rhythm and symptoms of AF, but many patients do not respond well, and require surgical treatment.

Related Links:

Print article



view channel

J&J Medical Devices Companies Partners with Microsoft to Further Enable its Digital Surgery Solutions

The Johnson & Johnson Medical Devices Companies (JJMDC; New Brunswick, NJ, USA) will collaborate with Microsoft (Redmond, Wash., USA) to further enable and expand JJMDC’s secure and compliant digital... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.